Literature DB >> 8501346

T cell response to Mycobacterium tuberculosis.

I M Orme1, P Andersen, W H Boom.   

Abstract

The T cell-mediated acquired immune response to infection with Mycobacterium tuberculosis, both in humans and in experimental models in the mouse, is a complex event believed to involve a variety of T cell subsets that manifest themselves in numerous functions, including protection, delayed-type hypersensitivity, cytolysis, and the establishment of a state of memory immunity. These functions in turn involve the secretion of an array of cytokines, several of which direct cells of the monocyte/macrophage axis to contain and destroy the invading bacilli. This article reviews the development of these ideas, both from clinical experience and from basic research in animal models. In addition, the newly emerging hypothesis that the secreted or export proteins of M. tuberculosis are the key protective antigens leading to the initial expression of acquired specific resistance to this organism is examined.

Entities:  

Mesh:

Year:  1993        PMID: 8501346     DOI: 10.1093/infdis/167.6.1481

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  136 in total

1.  Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

Authors:  A Weinrich Olsen; L A van Pinxteren; L Meng Okkels; P Birk Rasmussen; P Andersen
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Antigen specificity of T-cell response to Mycobacterium avium infection in mice.

Authors:  T F Pais; J F Cunha; R Appelberg
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

3.  Cellular interactions in bovine tuberculosis: release of active mycobacteria from infected macrophages by antigen-stimulated T cells.

Authors:  E Liebana; A Aranaz; F E Aldwell; J McNair; S D Neill; A J Smyth; J M Pollock
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

4.  Stable T-cell population expressing an effector cell surface phenotype in the lungs of mice chronically infected with Mycobacterium tuberculosis.

Authors:  Ana Paula Junqueira-Kipnis; Joanne Turner; Mercedes Gonzalez-Juarrero; Oliver C Turner; Ian M Orme
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

5.  CD4 T cell depletion exacerbates acute Mycobacterium tuberculosis while reactivation of latent infection is dependent on severity of tissue depletion in cynomolgus macaques.

Authors:  Philana Ling Lin; Tara Rutledge; Angela M Green; Matthew Bigbee; Carl Fuhrman; Edwin Klein; JoAnne L Flynn
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-04       Impact factor: 2.205

6.  Characterization of T cells that confer a high degree of protective immunity against tuberculosis in mice after vaccination with tumor cells expressing mycobacterial hsp65.

Authors:  C L Silva; M F Silva; R C Pietro; D B Lowrie
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

7.  Interleukin-12 production by human monocytes infected with Mycobacterium tuberculosis: role of phagocytosis.

Authors:  S A Fulton; J M Johnsen; S F Wolf; D S Sieburth; W H Boom
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

8.  ESAT-6 subunit vaccination against Mycobacterium tuberculosis.

Authors:  L Brandt; M Elhay; I Rosenkrands; E B Lindblad; P Andersen
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

9.  Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by Mycobacterium tuberculosis.

Authors:  J R Webb; T S Vedvick; M R Alderson; J A Guderian; S S Jen; P J Ovendale; S M Johnson; S G Reed; Y A Skeiky
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

10.  Characterization of a 10- to 14-kilodalton protease-sensitive Mycobacterium tuberculosis H37Ra antigen that stimulates human gamma delta T cells.

Authors:  W H Boom; K N Balaji; R Nayak; K Tsukaguchi; K A Chervenak
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.